01 Rising Adoption of Smart Inhalation Platforms for Biologic Drug Delivery The inhaled biologics market is witnessing a shift toward smart inhalation platforms that combine biologic therapies with digital monitoring technologies. These systems help track inhaler usage, optimize dosing accuracy, and improve patient adherence in chronic respiratory disease management. For example, connected inhaler technologies developed by companies such as AstraZeneca are supporting digitally enabled respiratory care approaches by integrating treatment monitoring with patient management solutions.
02 Growing Development of Targeted Pulmonary Delivery Technologies for Complex Biologics A major trend in the inhaled biologics market is the advancement of specialized delivery technologies that improve lung deposition of complex biologic molecules. Challenges related to molecule stability and absorption are driving innovation in aerosol formulations and device platforms. For example, Insmed Incorporated received FDA approval for Arikayce (amikacin liposome inhalation suspension), the first inhaled liposomal antibiotic approved for Mycobacterium avium complex lung disease, demonstrating the potential of advanced inhalation systems to deliver complex therapies directly to the lungs while reducing systemic exposure.
01 The inhaled biologics market forecasts continued investment activity driven by increasing focus on targeted respiratory therapies, rising prevalence of chronic lung diseases, and advancements in inhalation biologic delivery platforms.
02 Key Investment and Funding Activities in Inhaled Biologics Market, 2025–2026 Company Funding/Investment (USD) Details Kinaset Therapeutics USD 103 million (Series B financing) In January 2026, Kinaset raised Series B funding to progress frevecitinib, an inhaled pan-JAK inhibitor, through Phase 2 studies for severe asthma. Avalyn Pharma Inc. USD 100 million (Series D financing) In July 2025, Avalyn completed an oversubscribed Series D round to advance clinical development of inhaled therapies targeting pulmonary fibrosis and other severe pulmonary diseases.
01 The inhaled biologics market is sensitive to disruptions due to its dependence on specialized biologic manufacturing, complex supply networks, cold-chain logistics, and availability of advanced inhalation delivery components. Supply chain disruptions have reshaped the market ecosystem by creating challenges in raw material procurement, clinical trial timelines, production scalability, and global distribution of biologic therapies. These disruptions have affected the industry worldwide by increasing manufacturing costs, causing delays in product launches, and influencing healthcare providers’ access to innovative respiratory treatments. The market is expected to follow an S-shaped recovery, with gradual stabilization driven by improved supply chain resilience, expanded manufacturing capabilities, diversified sourcing strategies, and increasing adoption of advanced inhaled biologic therapies.
01 Rising Prevalence of Chronic Respiratory Diseases and Increasing Focus on Needle-Free Administration Drive Market The increasing burden of asthma, chronic obstructive pulmonary disease, pulmonary fibrosis, and other respiratory disorders is driving demand for advanced inhaled biologic treatments. The growing patient population with uncontrolled respiratory conditions is encouraging pharmaceutical companies to develop therapies that provide localized action in the lungs with improved efficacy and reduced systemic effects. For example, AstraZeneca and Amgen are advancing tezepelumab delivery research for severe asthma, building on the success of Tezspire, an anti-TSLP biologic approved for severe asthma management. These developments highlight increasing interest in biologics targeting inflammatory pathways involved in respiratory diseases and support market expansion.The growing preference for non-invasive and patient-friendly drug administration methods is driving demand for inhaled biologic therapies as an alternative to conventional injectable biologics. Patients with chronic respiratory conditions often require long-term treatments, creating the need for convenient delivery options that improve adherence and reduce treatment burden. For example, Boehringer Ingelheim is developing inhaled biologic approaches, including pulmonary delivery technologies for respiratory diseases, to explore more convenient administration routes for complex therapies.
01 Limited Reimbursement Coverage and High Treatment Costs Restrain Market Expansion Limited reimbursement support for newer inhaled biologic therapies reduces financial incentives for healthcare providers to adopt these treatments, particularly in cost-sensitive markets. Payers often require strong clinical and economic evidence before including innovative biologic therapies in coverage programs. Thus, inconsistent reimbursement policies restrain market growth by affecting treatment affordability and reducing patient access to advanced inhaled biologic solutions.Inhaled biologics generally involve higher pricing compared with traditional inhaled corticosteroids, bronchodilators, and other established respiratory treatments due to their complex development and manufacturing processes. This cost difference influences prescribing decisions and limits adoption among price-sensitive patient populations. Thus, the premium cost of inhaled biologic therapies remains a significant restraint affecting market penetration and volume growth.
01 Development of Inhaled Gene and RNA-Based Therapies and Increasing Adoption of Home-Based Respiratory Care Offer Growth Opportunities to Market Players The growing development of inhaled gene and RNA-based medicines creates a significant growth opportunity for biotechnology companies developing next-generation respiratory therapies. Direct pulmonary delivery can enable targeted treatment of genetic and inflammatory lung disorders while reducing systemic exposure. Companies such as Arcturus Therapeutics are exploring inhaled RNA delivery approaches for respiratory applications. Future adoption of inhaled nucleic acid therapies can expand the role of inhaled biologics beyond conventional protein-based treatments and create new therapeutics.The shift toward home-based management of chronic respiratory diseases creates growth opportunities for companies developing convenient inhaled biologic delivery systems. Patient-friendly inhalation technologies can support long-term therapy administration outside hospital settings while improving treatment adherence. Future integration of portable delivery devices and digital monitoring solutions can accelerate adoption of inhaled biologics in outpatient and home-care environments.
01 Complex Manufacturing Requirements and Need to Maintain Drug Stability and Efficient Pulmonary Delivery Challenge Market Growth The complex development and manufacturing processes for inhaled biologics require advanced formulation techniques, specialized equipment, and strict quality control to maintain biologic stability and delivery efficiency. These factors increase production costs and create challenges in scaling commercial manufacturing. Thus, high manufacturing complexity and cost requirements act as restraints by limiting accessibility and slowing broader adoption of inhaled biologic therapies.Biologic molecules are sensitive to environmental conditions and can experience stability issues during formulation, aerosolization, and storage processes. These limitations may impact drug potency, lung deposition efficiency, and therapeutic performance, requiring additional investments in research and development.
May 2026 MannKind Corporation received US FDA approval for Afrezza as the first and only inhaled mealtime insulin approved for children and adolescents aged 6 years and older.
January 2026 MannKind Corporation announced the expansion of its collaboration with United Therapeutics to accelerate development of ralinepag DPI (MNKD-1501), an inhaled dry-powder therapy for pulmonary arterial hypertension.